Evaluation of the Efficacy and Safety of Zinc in Viral Infections (VIZIR)

University of Monastir

Status

Completed

Conditions

SARS-CoV2 Infection

Treatments

Dietary Supplement: Zinc

Dietary Supplement: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT05212480

VIZIR.COV

Details and patient eligibility

About

The main objective of the clinical study is to evaluate the efficacy of Zinc supplementation in non-critically ill Covid-19 patients..

Full description

The VIZIR study is a national, longitudinal, multi-centre study conducted over a 3-month follow-up period.

The priori hypothesis was that supplementation with zinc would reduce 30-day mortality and need to intensive care unit (ICU) admission among non critically ill patients with Covid-19.

The VIZIR study will be carried out in Tunisia at the level of consultations of general practitioners of both sectors : public and liberal, as well as in the emergency services of Monastir and Sousse.

Enrollment

460 patients

Sex

All

Ages

18 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Age 18 years and over .
Sars-Cov2 infection Diagnosed with RT PCR , Rapid Test or Chest CT-Scan performed within the less than 5 days of symptoms.

Exclusion criteria

Patients who received zinc before the start of the protocol.
heart, liver, malignancies, or renal failure (estimated glomerular filtration rate ≤30 mL/min/1.73 m2);
Mental disorders .
Chronic Dialysis.
Hospitalisation in ICU (use of respiratory or cardiovascular organ support (oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes). .
Known hypersensitivity to zinc.
unsuitability for oral administration